Rosa Del Mar

Daily Brief

Issue 68 2026-03-09

Glp-1 Mainstreaming And Parallel Supply Chains

Issue 68 Edition 2026-03-09 9 min read
General
Sources: 1 • Confidence: Medium • Updated: 2026-03-09 14:42

Key takeaways

  • Nearly one in seven Americans is taking a GLP-1 drug, and roughly 20% have tried one.
  • Because BPC-157 is systemic, self-experimenters cannot create a true within-person control comparison such as comparing one shoulder to the other.
  • Using longer exhales reduces heart rate via vagal pathways (respiratory sinus arrhythmia), and a long-exhale pattern can reduce momentary anxiety.
  • A UK study of over 80,000 people reported that brighter days and darker nights are associated with better mental health outcomes across multiple psychiatric conditions.
  • People are more likely to adopt health protocols when they understand underlying mechanisms because mechanistic understanding increases perceived flexibility and adherence beyond 'top-10 tips' lists.

Sections

Glp-1 Mainstreaming And Parallel Supply Chains

  • Nearly one in seven Americans is taking a GLP-1 drug, and roughly 20% have tried one.
  • Retatrutide has completed Phase 3 at Lilly and enables rapid weight loss with some muscle sparing and fewer side effects than earlier GLP drugs.
  • The primary safety concern for compounded GLP/peptide products is contamination risk due to weaker regulation than traditional drug manufacturing.
  • Gray-market peptides often include test sheets and claim high purity, while black-market peptides may not match the vial label.
  • Compounding pharmacies and gray-market sellers are selling retatrutide even though it is not legal, and enforcement is inconsistent.
  • Widespread GLP-class use could theoretically eradicate obesity because some users can lose up to about one-third of body weight.

Peptide Interventions: Efficacy Claims Vs Evidence And Safety Uncertainty

  • Because BPC-157 is systemic, self-experimenters cannot create a true within-person control comparison such as comparing one shoulder to the other.
  • BPC-157 appears to promote cartilage growth, nerve regrowth, and vascular growth, and could be harmful if it vascularizes an existing tumor.
  • Growth hormone secretagogues stimulate pituitary growth hormone release (they are not growth hormone) and are typically taken before sleep to increase deep sleep, growth hormone, and IGF-1.
  • Andrew Huberman tried pinealon, observed about three hours of REM sleep per night, and stopped due to limited human data and concern about stimulating pineal cell proliferation.
  • Melanotan use is risky because some skin color changes may be permanent and there is a risk of priapism that can damage nerves and penile tissue.
  • Within about five years, peptide-based 'cocktails' delivered via a pill or injection will become commonplace and low-cost, similar to mainstream supplements like vitamin D or creatine.

Stress Physiology Interpretation And Interventions

  • Using longer exhales reduces heart rate via vagal pathways (respiratory sinus arrhythmia), and a long-exhale pattern can reduce momentary anxiety.
  • Transient daytime cortisol spikes are not problematic if cortisol reliably returns to baseline afterward, while impaired post-stress cortisol recovery is the key issue.
  • A cortisol rhythm shifted later in the day is associated with worse cancer outcomes and reduced longevity.
  • Narrow single-point visual focus tends to increase arousal and attentional energy, while panoramic or dilated gaze tends to shift the nervous system toward calmer states.
  • Using cortisol-lowering supplements like ashwagandha is context- and timing-dependent, with morning use being counterproductive for circadian cortisol needs and prolonged high dosing risking off-target effects.
  • A 'read-then-write' approach to physiology is to map normal biological activity patterns and then apply targeted interventions to shift specific variables like cortisol.

Sleep And Circadian Control Moving From Measurement To Intervention

  • A UK study of over 80,000 people reported that brighter days and darker nights are associated with better mental health outcomes across multiple psychiatric conditions.
  • Starchy carbohydrate intake can reduce elevated cortisol because cortisol mobilizes energy and raises blood glucose.
  • Cooling during sleep followed by warming the sleep environment in the last hour before waking can increase REM sleep without drugs.
  • Very low-starch or ketogenic diets can impair sleep for many people, while moderate carbohydrates at dinner (especially after resistance training and not too close to bedtime) may improve sleep continuity.
  • Sleep technology is expected to shift from measuring sleep to inducing sleep using localized cooling (palms/soles), eye-movement masks to accelerate sleep onset, and integrated bright-light delivery on waking.

Ai-Enabled Continuous Diagnostics And Behavior Change Tooling

  • People are more likely to adopt health protocols when they understand underlying mechanisms because mechanistic understanding increases perceived flexibility and adherence beyond 'top-10 tips' lists.
  • Andrew Huberman uses the Claude model to generate quizzes and tests for self-assessment of knowledge.
  • AI systems will increasingly unify EHR records, wearable streams, blood tests, and imaging to detect health issues before symptoms; early signals were seen when wearables flagged COVID prior to subjective illness.
  • A 'read-then-write' approach to physiology is to map normal biological activity patterns and then apply targeted interventions to shift specific variables like cortisol.

Watchlist

  • Banking one's own post-exercise blood for later autologous infusion is proposed as a near-term low-bar rejuvenation and recovery strategy, based on claims that exercise-blood infusions are beneficial and injury-related circulating factors can be harmful.

Unknowns

  • What is the primary source, methodology, and definition set behind the stated GLP-1 prevalence and 'tried' rates?
  • What are the published clinical results and regulatory status details for retatrutide, including muscle-sparing claims and side-effect comparisons?
  • How prevalent is illegal or quasi-legal retatrutide distribution via compounding and gray markets, and what enforcement actions are occurring in practice?
  • What is the observed rate and nature of contamination/adverse events attributable to compounded peptide/GLP products versus regulated products?
  • What controlled human evidence exists for BPC-157’s tissue-repair claims and for the proposed angiogenesis/tumor-vascularization risk?

Investor overlay

Read-throughs

  • GLP-1 demand may be expanding faster than regulated supply, supporting parallel channels such as compounding and gray markets. Quality assurance and enforcement variability could become key constraints and sources of differentiation for legitimate supply and verification services.
  • Rising interest in peptides for performance, sleep, and repair may drive spend on testing, safety screening, and trusted distribution, but the decision environment is high uncertainty with potentially severe downside risks if contamination or adverse events rise.
  • Shift from measurement to intervention in sleep, circadian, and stress control plus the claim that mechanistic explanations improve adherence may support AI-enabled monitoring and coaching tools that integrate records and continuous sensing, contingent on real-world uptake beyond speculation.

What would confirm

  • Credible, well-defined prevalence and adoption metrics for GLP-1 usage, plus sustained reports of shortages or access friction, alongside documented growth in compounding or gray-market activity and enforcement actions.
  • Published controlled human evidence and regulatory clarity for next-generation GLP agents such as retatrutide, including side-effect and body-composition outcomes, and quantified contamination or adverse-event rates for compounded versus regulated products.
  • Demonstrated deployment of tools that integrate clinical records with continuous sensing for presymptomatic detection, plus measured adherence improvements when mechanistic explanations are used versus simple tip lists.

What would kill

  • Revisions or clarifications that materially lower GLP-1 prevalence or trial rates, or evidence that regulated supply meets demand without persistent access constraints, reducing incentives for parallel sourcing.
  • Robust data showing low incremental contamination or adverse-event risk for compounded or gray-market peptide and GLP products, or strong enforcement that rapidly suppresses non-traditional channels.
  • Weak user retention or no measurable behavior change from mechanistic education and monitoring workflows, or lack of practical integration of clinical records and sensing streams into usable consumer or clinical products.

Sources